Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-04-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and the relationship between the reporting entity (Celltrion) and the issuer (Celltrion Pharm). This type of document is a mandatory regulatory disclosure regarding significant share ownership and changes in control, which falls under the 'Major Shareholding Notification' category.
2024-04-08 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과) for Celltrion Pharm. It details the outcomes of various agenda items such as financial statement approval, dividend decisions, and the election of board members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2024-03-26 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of the CEO (Representative Director) of Celltrion Pharm. It details the outgoing CEO, the incoming CEO (Yoo Young-ho), the reason for the change, and the date of the board resolution. This falls directly under the category of board/management changes.
2024-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of corporate action regarding capital structure and equity-based compensation is best classified as a regulatory filing under the RNS category, as it does not fit into specific categories like M&A, dividends, or director dealings.
2024-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) by Celltrion Pharm. It provides the audit opinion (unqualified/proper), key financial data, and auditor information. While it contains financial data, it is a regulatory filing announcing the completion and submission of the audit report to the exchange, rather than the full annual report or a standalone audit report document itself. Therefore, it fits the definition of a Report Publication Announcement (RPA). FY 2023
2024-03-18 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive financial report titled '재무제표에 대한 감사보고서' (Audit Report on Financial Statements) for Celltrion Pharm, covering the fiscal year 2023. It includes the independent auditor's report, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes (주석). While it contains an audit opinion, it is a full set of audited financial statements rather than a standalone audit report or a summary. In the context of financial reporting, this constitutes the official annual financial disclosure, which is classified as an Annual Report (10-K) equivalent in this taxonomy. FY 2023
2024-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.